The investigators seek to investigate certain patient characteristics that would predict the
response to a currently approved analgesic, pregabalin, in patients with chronic pain due to
nerve damage caused by chemotherapy. Patients with this painful condition, called
chemotherapy-induced peripheral neuropathy (CIPN) have a current or recent history of
chemotherapy with particular chemotherapy agents called taxanes or oxaliplatin. The
investigators will recruit potential subjects from both the Siteman Cancer Center and the
Washington University Pain Management Center. Those patients who meet the inclusion and
satisfy the exclusion criteria will be enrolled. Subjects will undergo mechanical and thermal
sensitivity testing on their extremities, will provide quality of life information by
completing questionnaires and will receive pregabalin followed by placebo, or placebo
followed by pregabalin [crossover design] in order to assess how well the sensory tests
predict the analgesic effect of pregabalin (compared to placebo).